On this page ▾
Key takeaways
- A US clinic review found 91.5% of 212 Lenire patients improved by more than seven THI points.
- It had no control group, relied on patients' own scores and did not verify device use.
- One author helped develop Lenire, so independent long-term research is still needed.
- The 2023 US approval rested on TENT-A3, a 112-person trial without a separate control group.
- The NHS lists digital CBT, sound therapy, counselling and hearing aids for tinnitus; ask a clinician about Lenire.
A real-world study from a US clinic reports that 91.5% of 212 tinnitus patients with data improved by more than seven points on the Tinnitus Handicap Inventory after about 12 weeks of Lenire treatment1. The review had no control group, and one of its two authors helped develop the device, so it cannot prove the device works.
About one in seven people has tinnitus, more than 7 million in the UK2. The NHS lists digital cognitive behavioural therapy, sound therapy, counselling and hearing aids as treatments3. Our piece on four decades of progress in tinnitus relief puts newer devices in context.
What did the Lenire real-world study find?
The study, from the Alaska Hearing and Tinnitus Center, was published in Communications Medicine. It was a single-arm retrospective chart review of 220 patients treated with Lenire between May 2023 and June 2024. Of 212 patients with data, 91.5% improved by more than seven points on the Tinnitus Handicap Inventory (THI), the study's threshold for clinical benefit. The average improvement was 27.8 points, and there were no device-related serious adverse events1.
How does Lenire work?
Lenire is a form of bimodal neuromodulation: it combines sound played through headphones with mild electrical pulses delivered to the tongue. It is designed to change how the brain responds to tinnitus, although the exact mechanism is not fully established. It is used under the guidance of a trained audiologist, and the manufacturer's standard protocol is two 30-minute sessions a day.
It builds on earlier trials, notably TENT-A3, a trial of 112 people who each had sound-only treatment first and then Lenire, which supported Lenire's US approval in March 2023. The manufacturer reports that about 89% of participants said they would recommend the treatment. The THI is a widely used questionnaire that measures how much tinnitus affects daily life4.
How strong is the evidence?
Dr Emily E McMahan, an audiologist and co-author of the study, said: “The publication of these data underscores the effectiveness of Lenire when patients are supported by experienced clinicians. It’s an encouraging step forward in how we manage tinnitus.”
Safety outcomes were also positive, with no device-related serious adverse events reported1. The device is now used in Europe and the United States.
Professor Hubert Lim, a co-author of the study and one of the scientists behind Lenire, said the results point to a broader shift: “Obtaining real-world outcomes that surpass even those from our controlled clinical trials marks a significant advancement. It suggests that with clinician support, we can move towards more reliable, evidence-based therapies for tinnitus.”
Micaela Stonestreet, a Clinical Audiologist at Hearology, which provides support and diagnostic services for people with tinnitus in the UK, commented, “There is a long history of products claiming to help with tinnitus, so we approach each new solution with a healthy degree of scepticism. When considering new treatments, it’s essential to examine the supporting evidence critically.
“Lenire has undergone testing both in controlled research settings and also in everyday clinical practice. The most robust evidence comes from the TENT-A3 trial, a formal clinical study designed in consultation with the U.S. Food and Drug Administration (FDA). The study adhered to strict protocols, monitored device usage, and ultimately formed the basis for Lenire’s FDA approval in 2023.
“By contrast, a more recent real-world study conducted at a single private clinic in Alaska assessed how Lenire performs in routine care. However, unlike a clinical trial, this study lacked a control group, relied on self-reporting from the participants, and did not verify device usage. It’s also important to note that both authors of this study had financial ties to the device manufacturer.
“Taken together, these studies indicate that Lenire could be a promising option for people with moderate or severe tinnitus. However, whilst early results are definitely encouraging, further independent research and long-term data will be crucial to fully establish the effectiveness of this new device and procedure in treating tinnitus.”
If tinnitus has worn you down, wanting to try something new is understandable, and the evidence is worth checking first. If you are living with tinnitus, see a GP if it is constant, is getting worse or affects your sleep, concentration or mood3. Tinnitus after a head injury, or with sudden hearing loss, facial weakness or vertigo, needs A&E or 9993. A hearing test at any of our clinics can check whether hearing loss is involved. Our piece on when tinnitus becomes a warning sign explains the signs to watch for, and how emotional resilience shapes tinnitus recovery covers day-to-day coping.

Frequently asked questions
Is Lenire effective for tinnitus?
How does Lenire work?
Is Lenire available on the NHS?
What is the latest treatment for tinnitus?
References:
- [1] E. E. McMahan and H. H. Lim, "Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting," Communications Medicine, vol. 5, 2025, doi: 10.1038/s43856-025-00837-3.
- [2] RNID, "Prevalence of deafness, hearing loss and tinnitus," RNID facts and figures. Accessed: Nov. 16, 2026. [Online]. Available:
- [3] NHS, "Tinnitus," NHS website. Accessed: Nov. 15, 2026. [Online]. Available:
- [4] C. W. Newman, G. P. Jacobson, and J. B. Spitzer, "Development of the Tinnitus Handicap Inventory," Archives of Otolaryngology - Head & Neck Surgery, vol. 122, no. 2, pp. 143-148, Feb. 1996, doi: 10.1001/archotol.1996.01890140029007.

